Amarantus Bioscience Holdings Inc (AMBS)

[JJAAMMAANN]

ESS Update?
Wonder when we will get an update on the progress of the ESS CRADA?

Amarantus is developing ESS for the treatment of severe burns and is preparing to commence Phase 2 clinical studies in the third quarter of 2015. ESS has received orphan drug designation from the U.S. Food and Drug Administration for the treatment of hospitalized patients with deep partial and full thickness burns requiring grafting, and has an open corporate-sponsored IND under which the clinical study can proceed.

http://www.amarantus.com/news/press-releases/detail/2010/amarantus-bioscience-u-s-army-and-rutgers-university-in

Corporate Sponsored?
In My Own Personal Opinion Of Course!
Long AMBS!